• 1
    Jemal A, Siegel R, Ward E et al. Cancer statistics. CA Cancer J Clin 2006;56:10630.
  • 2
    Slomovitz BM, Burke TW, Eifel PJ et al. Uterine papillary serous carcinoma: a single institution review of 129 cases. Gynecol Oncol 2003;91:4639.
  • 3
    Nicklin JL, Copeland LJ. Endometrial papillary serous carcinoma: patterns of spread and treatment. Clin Obstet Gynecol 1996;39:68695.
  • 4
    Goff BA, Kato D, Schmidt RA et al. Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 1994;54:2648.
  • 5
    Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet 2003;83(Suppl. 1):11933.
  • 6
    Kurman RJ. Blaustein’s pathology of the female genital tract, 5th edn. Springer, 2002, p. 52833.
  • 7
    Matthews RP, Hutchinson-Colas J, Maiman M et al. Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol 1997;65:20612.
  • 8
    Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study of 108 cases with emphasis on prognostic significance of associated endometrioid carcinoma, absence of invasion and concomitant ovarian cancer. Gynecol Oncol 1992;47:298305.
  • 9
    Hamilton CA, Liou WS, Osann K et al. Impact of adjuvant therapy on survival of patients with early stage uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys 2005;63:83944.
  • 10
    Elit L, Kwon J, Bentley J et al. Optimal management for surgically Stage 1 serous cancer of the uterus. Gynecol Oncol 2004;92:2406.
  • 11
    Huh WK, Powell M, Leath CA et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol 2003;91:4705.
  • 12
    Levenback C, Burke TW, Silva E et al. Uterine papillary serous carcinoma (USPC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol 1992;46:31721.
  • 13
    Hung M, Lau Y. Basic science of HER-2/neu: a review. Semin Oncol 1999;26(Suppl. 12):519.
  • 14
    Busse D, Doughty RS, Arteaga CL. HER-2/neu (erbB-2) and the cell cycle. Semin Oncol 2000;27(Suppl. 11):38.
  • 15
    Karunagaran D, Tzahar E, Beerli RR et al. ErbB2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996;15:25464.
  • 16
    Graus-Porta D, Beerly RR, Daly JM, Hynes NE. ErbB2, the preferred heterodimerization partner of all erbB receptors is a mediator of lateral signalling. EMBO J 1997;16:164755.
  • 17
    Klijanienko J, Couturier J, Galut M et al. Detection and quantitation by fluorescence in situ hybridization FISH and image analysis of her2 neu gene amplification in breast cancer fine-needle samples. Cancer 1999;87:3128.
  • 18
    Berchuck A, Kamel A, Whitaker R et al. Overexpression of her2neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:408791.
  • 19
    Saffari B, Jones LA, El-Naggar A et al. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 1995;55:56938.
  • 20
    Ross JS, Sheehan C, Hayner-Buchan AM et al. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol 1997;28:82733.
  • 21
    Sato K, Moriyama M, Mori S et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992;70:24938.
  • 22
    Bellone S, Palmieri M, Gokden M et al. Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy. Gynecol Oncol 2003;91:23140.
  • 23
    Berchuck A, Rodriguez G, Kinney RB et al. Overexpression of HER2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164:1521.
  • 24
    Khalifa MA, Mannel RS, Haaway SD et al. Expression of EGFR, HER2/neu, p53 and PCNA in endometrioid, serous papillary and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994;53:8492.
  • 25
    Coronado PJ, Vidart JA, Lopez-Asenjo JA et al. p53 overexpression predicts endometrial carcinoma recurrence better than HER2/neu overexpression. Eur J Obstet Gynecol Reprod Biol 2001;98:1038.
  • 26
    Fleming GF, Sill MA, Thigpen JT et al. Phase II evaluation of trastuzumab in patients with advanced or recurrent endometrial carcinoma: A report on GOG 181B. Proc ASCO 2003. Abstract 1821.
  • 27
    Santin AD, Bellone S, Gokden M et al. Overexpression of HER2/neu in uterine serous papillary cancer. Clin Cancer Res 2002;8:12719.
  • 28
    Santin AD, Bellone S, Van Stedum S et al. Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol 2005;98:2430.
  • 29
    Slomovitz BM, Broaddus RR, Burke TW et al. HER2/neu overexpression and amplification in uterine serous papillary carcinoma. J Clin Oncol 2004;22:312632.
  • 30
    Masood S, Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech 2002;59:1028.
  • 31
    Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:78392.
  • 32
    Yamauchi H, Stearns V, Hides VF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:233456.
  • 33
    Press MF, Slamon DJ, Flom KJ et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095105.
  • 34
    Ellis IO, Dowsett M, Bartlett J. Recommendations for HER2 testing in the UK. J Clin Pathol 2000;53:8902.
  • 35
    Abrahamsen HN, Steiniche T, Nexo E. Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: a methodological study on lymph nodes from melanoma patients. J Mol Diagn 2003;5:3441.
  • 36
    Villella JA, Cohen A, Tiersten A et al. HER-2/neu expression in uterine papillary serous cancer [abstract]. (2003 ASCO Annual Meeting on Gynecologic Cancer). 2003. Abstract 1870.
  • 37
    Cianciulli AM, Guadagni F, Marzano R et al. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters. J Exp Clin Cancer Res 2003;22:26571.
  • 38
    Santin AD, Zhan F, Canè S et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer 2005;92:156173.
  • 39
    Santin AD, Zhan F, Bellone S et al. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. Br J Cancer 2004;90:181424.
  • 40
    Watters AD, Going JJ, Cooke TG, Bartlett JM. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003;77:10914.
  • 41
    Santin AD, Bellone S, Van Stedum S et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 2005;104:13917.
  • 42
    Varshney D, Zhou YY, Geller SA, Alsabeh R. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol 2004;121:707.
  • 43
    Salido M, Tusquets I, Corominas JM et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 2005;7:R26773.
  • 44
    Rossi E, Ubiali A, Cadei M et al. HER-2/neu in breast cancer. A comparative study between histology, immunohistochemistry and molecular technique (FISH). Appl Immunohistochem Mol Morphol 2006;14:12731.
  • 45
    Lavie O, Horneich G, Ben-Arie A et al. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 2004;92:5214.